NRX Pharmaceuticals (NRXP) Payables (2017 - 2026)

NRX Pharmaceuticals (NRXP) has reported Payables for 10 consecutive years, with $21.7 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Payables rose 9.05% year-over-year to $21.7 million in Q2 2026; TTM through Jun 2026 was $21.7 million, a 9.05% increase from a year earlier, with the FY2025 full-year figure at $16.6 million, up 69.66% from the prior year.
• Payables was $21.7 million for Q2 2026 at NRX Pharmaceuticals, up from $13.2 million in the prior quarter.
• Over five years, Payables peaked at $21.7 million in Q2 2026 and troughed at $2.2 million in Q3 2022.
• A 5-year average of $12.2 million and a median of $13.4 million in 2023 frame the typical range for Payables.
• Across the five-year window, Payables sank 89.36% in 2022 and jumped 516.01% in 2023, its largest moves.
• Over 5 years, Payables stood at $9.8 million in 2022, then surged by 41.05% to $13.8 million in 2023, then slipped by 29.17% to $9.8 million in 2024, then jumped by 69.66% to $16.6 million in 2025, then surged by 30.9% to $21.7 million in 2026.
• The last three Payables figures came in at $21.7 million (Q2 2026), $13.2 million (Q1 2026), and $16.6 million (Q4 2025), per Business Quant data.